Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
Moleculin Biotech (Nasdaq: MBRX) reported preliminary unblinded interim results from the first 45 patients in Part A of its Phase 2/3 MIRACLE trial in relapsed/refractory AML. Complete remission (CR) was 43% and 36% for Annamycin dose arms vs 12% control; composite CR (CRc) was 50% and 57% vs 29%. The iDMC said there was a numeric CR trend favoring Annamycin but no statistical significance and recommended continuing; 67/90 Part A patients are enrolled.
How this was made
The 30-second read
Why it matters
The interim unblinded Part A results show both Annamycin dose arms outperforming control on complete remission (CR) and composite complete remission (CRc), and the iDMC recommended continuing without dropping either arm—supporting continued trial progression toward later analyses.
Market read
Traders can reassess MBRX’s clinical probability-of-success based on concrete interim remission-rate differentials vs randomized control, plus the iDMC continuation decision.
What to watch
The iDMC found efficacy data too similar between the two Annamycin dose arms to drop either, implying dose selection risk remains; additional Part A database review/readout could change interpretation.
Background
MIRACLE is a pivotal Phase 2/3, randomized, double-blind, placebo-controlled adaptive trial of L-Annamycin (naxtarubicin) plus cytarabine vs placebo plus cytarabine in adult relapsed/refractory AML; Part A selects the optimal dose before advancing to the pivotal portion.
Ticker impact
Moleculin reported interim unblinded Phase 2/3 MIRACLE Part A results where both Annamycin arms showed higher CR (43%/36%) vs control (12%).
Likely near-term positive bias for MBRX as traders price improved trial odds, though magnitude may be tempered by lack of statistical significance at this interim look.
The article provides specific remission-rate datapoints and iDMC continuation decision, but explicitly notes no statistical significance at the first interim analysis and that results are based on only the first 45 patients.
Market effects
Reinforces investor appetite for AML relapse therapies and anthracycline-like approaches, potentially lifting sentiment for adjacent clinical-stage oncology names.
Primarily US biotech sentiment; limited direct regional spillover beyond Nasdaq small/mid-cap biotech flows.
Could modestly influence global AML trial-risk perception, but impact is mostly company-specific until later, statistically significant readouts.
Counterpoint
No statistical significance at this interim analysis and single-cycle measurement can overstate durability; later interim/final data may fail to confirm the numeric trend.
Key entities
- companyMoleculin Biotech, Inc.
Nasdaq-listed company advancing L-Annamycin (naxtarubicin) in the MIRACLE trial for R/R AML.
- drugL-Annamycin (naxtarubicin)
Experimental anthracycline intended to avoid multidrug resistance and cardiotoxicity; tested in two dose arms plus high-dose cytarabine.
- clinical_trialMIRACLE trial (MB-108)
Pivotal adaptive Phase 2/3 randomized double-blind study; Part A is dose selection based on interim efficacy.
- oversight_bodyIndependent Data Monitoring Committee (iDMC)
Reviewed interim data and recommended continuing the trial; noted strong numeric trend but no statistical significance for CR.
